These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

817 related items for PubMed ID: 30929895

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK, NOR-SWITCH study group.
    Lancet; 2017 Jun 10; 389(10086):2304-2316. PubMed ID: 28502609
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn's disease.
    Oike T, Akizue N, Ohta Y, Koseki H, Saito M, Yokoyama Y, Imai Y, Taida T, Okimoto K, Saito K, Ogasawara S, Matsumura T, Nakagawa T, Arai M, Katsuno T, Fukuda Y, Kitsukawa Y, Kato J, Kato N.
    Arab J Gastroenterol; 2024 Aug 10; 25(3):257-262. PubMed ID: 38714472
    [Abstract] [Full Text] [Related]

  • 6. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C, Srinivasan A, An YK, Picardo S, van Langenberg D, Menon S, Begun J, Ghaly S, Thin L.
    Med J Aust; 2021 Feb 10; 214(3):128-133. PubMed ID: 33070332
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K, Rutka M, Ferenci T, Nagy F, Bálint A, Bor R, Milassin Á, Fábián A, Szántó K, Végh Z, Kürti Z, Lakatos PL, Szepes Z, Molnár T.
    Expert Opin Biol Ther; 2017 Nov 10; 17(11):1325-1332. PubMed ID: 28819991
    [Abstract] [Full Text] [Related]

  • 9. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ.
    Expert Rev Gastroenterol Hepatol; 2015 Nov 10; 9 Suppl 1():35-44. PubMed ID: 26395533
    [Abstract] [Full Text] [Related]

  • 10. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J.
    Arthritis Res Ther; 2016 Jan 20; 18():25. PubMed ID: 26795209
    [Abstract] [Full Text] [Related]

  • 11. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
    Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J.
    Scand J Gastroenterol; 2016 Sep 20; 51(9):1062-8. PubMed ID: 27002981
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A, Huoponen S, Pahikkala T, Blom M, Arkkila P, Sipponen T.
    Scand J Gastroenterol; 2017 Dec 20; 52(12):1348-1353. PubMed ID: 28838273
    [Abstract] [Full Text] [Related]

  • 14. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
    Hanauer SB, Sands BE, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Yang S, Lee J, Lee J, Kim JM, Park G, Sandborn WJ, Colombel JF.
    Gastroenterology; 2024 Oct 20; 167(5):919-933. PubMed ID: 38788861
    [Abstract] [Full Text] [Related]

  • 15. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M.
    Eur J Gastroenterol Hepatol; 2017 Nov 20; 29(11):1290-1295. PubMed ID: 28902041
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study.
    Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J.
    Ann Intern Med; 2019 Jan 15; 170(2):99-107. PubMed ID: 30534946
    [Abstract] [Full Text] [Related]

  • 17. Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
    Park J, Cheon JH, Lee KM, Kim YH, Ye BD, Eun CS, Kim SH, Lee SH, Lee JH, Schreiber S.
    Gut Liver; 2023 May 15; 17(3):430-440. PubMed ID: 35975641
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
    Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK.
    J Intern Med; 2019 Jun 15; 285(6):653-669. PubMed ID: 30762274
    [Abstract] [Full Text] [Related]

  • 19. Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease.
    Sieczkowska-Golub J, Meglicka M, Plocek A, Banaszkiewicz A, Jarzębicka D, Toporowska-Kowalska E, Gawronska A, Oracz G, Kierkus J.
    J Pediatr Gastroenterol Nutr; 2017 Sep 15; 65(3):285-288. PubMed ID: 28542043
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.